Univ. Prof. Dr. Bernd Jilma

work address:

Medical University of Vienna, Department of Clinical Pharmacology, Währinger Gürtel 18-20, 1090 Vienna       

e-mail:

bernd.jilma@meduniwien.ac.at         

homepage:

klpharm.meduniwien.ac.at/organization/section-of-hematology-immunology/          

know-how and research interests:

Our group is interested in platelet function and coagulation in various clinical settings but particularly emergencies, and critically ill patients with disseminated intravascular coagulation, thrombotic thrombocytopenic purpura, resuscitated as well as stroke patients. We are using a human endotoxemia model to characterize the mechanism of action of various investigational anticoagulants and anti-inflammatory drugs in phase I trials, and have recently established a model of endotoxin instillation into the lung. We also focus on high on treatment platelet reactivity in patients taking P2Y12 inhibitors, and have been investigating drug-drug interactions of anti-platelet drugs, and the pharmacodynamic effects of aptamers on coagulation and platelets

research topic:

Coagulation and platelet function in inflammation and critically ill patients

techniques and infrastructure of the research group:

Phase I research ward, human endotoxemia model, endotoxin instillation in the lung, various models of extracorporeal circulation, platelet function analysis, analysis of in vivo markers of clotting, flow cytometry, enzyme linked immunoassays, chemoluminescence assays, RT-PCR, high performance liquid chromatography, expression and purification of recombinant proteins as well as mass spectrometry in collaboration with BOKU & KIMCL          

publications:

Caplacizumab for Acquired Thrombotic Thrombozytopenic Purpura.

Peyvandi F, Sully M, Kremer Hovinga JA, Cataland S, Knöbl P, Wu H, Artoni W, Westwood JP, Mansouri Taleghani M, Jilma B, Callewaert F, Ulrichs H, Duby C, Tersago D; TITAN Investigators.  N Engl J Med. 2016 Feb 11;374(6):511-522.

Caplacizumab Treatment for Acquired Thrombotic Thrombocytopenic Purpura.

Scully M, Cataland SR, Peyvandi F, Coppo P, Knöbl P, Kremer Hovinga JA, Metjian A, de la Rubia J, Pavenski K, Callewaert F, Biswas D, De Winter H, Zeldin RK; HERCULES Investigators. N Engl J Med. 2019 Jan 24;380(4):335-346. doi: 10.1056/NEJMoa1806311. Epub 2019 Jan 9. PMID: 30625070 Clinical Trial.

Routine haematological parameters in COVID-19 prognosis.

Pereyra D, Heber S, Jilma B, Zoufaly A, Assinger A. Lancet Haematol. 2020 Oct;7(10):e709. doi: 10.1016/S2352-3026(20)30286-6. PMID: 32976747 Free PMC article.

Risk of venous thromboembolism in patients with COVID-19: A systematic review and meta-analysis.

Nopp S, Moik F, Jilma B, Pabinger I, Ay C. Res Pract Thromb Haemost. 2020 Sep 25;4(7):1178-91. doi: 10.1002/rth2.12439. Online ahead of print.

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial.

Jäger U, D'Sa S, Schörgenhofer C, Bartko J, Derhaschnig U, Sillaber C, Jilma-Stohlawetz P, Fillitz M, Schenk T, Patou G, Panicker S, Parry GC, Gilbert JC, Jilma B. Blood. 2019 Feb 28;133(9):893-901. doi: 10.1182/blood-2018-06-856930. Epub 2018 Dec 17.